Q2 2024 EPS Estimates for Eli Lilly and Company Reduced by Analyst (NYSE:LLY)

Eli Lilly and Company (NYSE:LLY) – Analysts at Leerink Partnrs lowered their Q2 2024 earnings estimates for Eli Lilly and Company in a research note issued on Wednesday, May 1st. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of $2.41 per share for the quarter, down from their previous forecast of $2.45. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $13.50 per share.

Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday. Barclays lifted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research report on Tuesday. Citigroup boosted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $757.95.

Eli Lilly and Company Stock Down 2.7 %

Shares of NYSE LLY opened at $755.91 on Thursday. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $414.31 and a 52 week high of $800.78. The firm’s fifty day moving average is $761.75 and its 200 day moving average is $670.56. The company has a market cap of $718.24 billion, a price-to-earnings ratio of 111.33, a PEG ratio of 1.58 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The company had revenue of $8.77 billion for the quarter, compared to the consensus estimate of $8.94 billion. During the same period in the previous year, the firm earned $1.62 earnings per share. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis.

Institutional Trading of Eli Lilly and Company

Hedge funds and other institutional investors have recently modified their holdings of the business. Lipe & Dalton bought a new position in Eli Lilly and Company in the 4th quarter worth about $26,000. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company in the 3rd quarter worth about $27,000. Tidemark LLC bought a new position in Eli Lilly and Company in the 4th quarter worth about $29,000. Core Wealth Advisors Inc. boosted its stake in Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares in the last quarter. Finally, Legacy Financial Group LLC bought a new position in Eli Lilly and Company in the 3rd quarter worth about $35,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.